Global Cytology and HPV Testing Market

Cytology and HPV Testing Comprehensive Study by Type (Systems, Assay Kits, Services), Application (Cervical Cancer Screening Test, Head and Neck Cancer Screening Test, Molecular Diagnostics, Research Use, Other), End-Use (Hospitals, Clinics, Research Institutes), Test Type (DNA-based Test, RNA-based Test) Players and Region - Global Market Outlook to 2028

Cytology and HPV Testing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Cytology, also known as cell biology and cytopathology, is the study of cell composition, structure, and interactions between cells and their surroundings. It also studies cell structure, which aids in an illness diagnosis. The human papillomavirus (HPV) is a family of over 100 viruses. They can affect the moist membranes of the mouth and throat, as well as the anus, vagina, and vulva. The skin of the human body, as well as the trachea, bronchi, inner nose, mouth, and inner eyelids, are all affected. The demand for cervical cancer screening programs is increasing as the number of instances of cervical cancer rises. The tests have been discovered to resolve flaws in standard cervical screening, which has led to the development of alternative screening paradigms such as those based on the detection of the human papillomavirus (HPV). Men's genital parts, especially the skin on and around the penis and anus, can be infected with HPV. Infections of the mouth and throat can also be transmitted. Cervical cancer screening is an important element of a woman's healthcare regimen. An HPV test is advised for women over the age of 30 to detect the virus. The screening aids in the detection of HPV-related precancerous lesions so that they can be eliminated.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledRoche Holding AG (Switzerland), Agilent Technologies, Inc. (United States), Becton, Dickinson and Company (United States), Qiagen N.V. (Germany), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States), Hologic Inc. (United States), Cepheid Inc. (United States), Seegene Inc. (South Korea), Takara Bio Inc. (Japan) and Promega Corporation (United States)


This growth is primarily driven by Increasing Number of Cervical Cancer Cases and Growing Cervical Cancer Screening Awareness Plans.

Globally, a noticeable market trend is evident High occurrence rate of HPV infections Major Players, such as Roche Holding AG (Switzerland), Agilent Technologies, Inc. (United States), Becton, Dickinson and Company (United States), Qiagen N.V. (Germany), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States), Hologic Inc. (United States), Cepheid Inc. (United States), Seegene Inc. (South Korea), Takara Bio Inc. (Japan) and Promega Corporation (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market is highly competitive with several local and global players present in the market. The major players are trying various new technologies and marketing techniques to gain a competitive advantage in the market.

Key Developments in the Market:
In August 2023, Hologic Inc. announced the acquisition of MobiLab Inc., a developer of point-of-care diagnostics for sexually transmitted infections (STIs), including HPV. This acquisition expands Hologic's portfolio of STI testing solutions and strengthens its position in the women's health market.
In March 2022, Qiagen N.V. announced the acquisition of Invirase Inc., a developer of liquid biopsy tests for cervical cancer. This acquisition expands Qiagen's portfolio of cancer diagnostics and provides it with access to Invirase's proprietary technology for detecting HPV DNA in liquid samples.

Influencing Trend:
High occurrence rate of HPV infections and Increasing Number of Cervical Cancer Screening Programs

Market Growth Drivers:
Increasing Number of Cervical Cancer Cases and Growing Cervical Cancer Screening Awareness Plans

Challenges:
High Cost of the Test and Low participation rates

Restraints:
Safety Issues and Diagnostic Accuracy Issues with Cytopathological Tests

Opportunities:
Increasing Technological Advancements and Increasing Standardization of Pathological Laboratories

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Cytology and HPV Testing Market
- Analysis about New Entrants in Cytology and HPV Testing Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Cytology and HPV Testing Study Sheds Light on
— The Cytology and HPV Testing Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cytology and HPV Testing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cytology and HPV Testing industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Systems
  • Assay Kits
  • Services
By Application
  • Cervical Cancer Screening Test
  • Head and Neck Cancer Screening Test
  • Molecular Diagnostics
  • Research Use
  • Other
By End-Use
  • Hospitals
  • Clinics
  • Research Institutes

By Test Type
  • DNA-based Test
  • RNA-based Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cervical Cancer Cases
      • 3.2.2. Growing Cervical Cancer Screening Awareness Plans
    • 3.3. Market Challenges
      • 3.3.1. High Cost of the Test
      • 3.3.2. Low participation rates
    • 3.4. Market Trends
      • 3.4.1. High occurrence rate of HPV infections
      • 3.4.2. Increasing Number of Cervical Cancer Screening Programs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cytology and HPV Testing, by Type, Application, End-Use, Test Type and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cytology and HPV Testing (Value)
      • 5.2.1. Global Cytology and HPV Testing by: Type (Value)
        • 5.2.1.1. Systems
        • 5.2.1.2. Assay Kits
        • 5.2.1.3. Services
      • 5.2.2. Global Cytology and HPV Testing by: Application (Value)
        • 5.2.2.1. Cervical Cancer Screening Test
        • 5.2.2.2. Head and Neck Cancer Screening Test
        • 5.2.2.3. Molecular Diagnostics
        • 5.2.2.4. Research Use
        • 5.2.2.5. Other
      • 5.2.3. Global Cytology and HPV Testing by: End-Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Research Institutes
      • 5.2.4. Global Cytology and HPV Testing by: Test Type (Value)
        • 5.2.4.1. DNA-based Test
        • 5.2.4.2. RNA-based Test
      • 5.2.5. Global Cytology and HPV Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cytology and HPV Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agilent Technologies, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Becton, Dickinson and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Qiagen N.V. (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hologic Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cepheid Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Seegene Inc. (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Takara Bio Inc. (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Promega Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cytology and HPV Testing Sale, by Type, Application, End-Use, Test Type and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cytology and HPV Testing (Value)
      • 7.2.1. Global Cytology and HPV Testing by: Type (Value)
        • 7.2.1.1. Systems
        • 7.2.1.2. Assay Kits
        • 7.2.1.3. Services
      • 7.2.2. Global Cytology and HPV Testing by: Application (Value)
        • 7.2.2.1. Cervical Cancer Screening Test
        • 7.2.2.2. Head and Neck Cancer Screening Test
        • 7.2.2.3. Molecular Diagnostics
        • 7.2.2.4. Research Use
        • 7.2.2.5. Other
      • 7.2.3. Global Cytology and HPV Testing by: End-Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Research Institutes
      • 7.2.4. Global Cytology and HPV Testing by: Test Type (Value)
        • 7.2.4.1. DNA-based Test
        • 7.2.4.2. RNA-based Test
      • 7.2.5. Global Cytology and HPV Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cytology and HPV Testing: by Type(USD Million)
  • Table 2. Cytology and HPV Testing Systems , by Region USD Million (2017-2022)
  • Table 3. Cytology and HPV Testing Assay Kits , by Region USD Million (2017-2022)
  • Table 4. Cytology and HPV Testing Services , by Region USD Million (2017-2022)
  • Table 5. Cytology and HPV Testing: by Application(USD Million)
  • Table 6. Cytology and HPV Testing Cervical Cancer Screening Test , by Region USD Million (2017-2022)
  • Table 7. Cytology and HPV Testing Head and Neck Cancer Screening Test , by Region USD Million (2017-2022)
  • Table 8. Cytology and HPV Testing Molecular Diagnostics , by Region USD Million (2017-2022)
  • Table 9. Cytology and HPV Testing Research Use , by Region USD Million (2017-2022)
  • Table 10. Cytology and HPV Testing Other , by Region USD Million (2017-2022)
  • Table 11. Cytology and HPV Testing: by End-Use(USD Million)
  • Table 12. Cytology and HPV Testing Hospitals , by Region USD Million (2017-2022)
  • Table 13. Cytology and HPV Testing Clinics , by Region USD Million (2017-2022)
  • Table 14. Cytology and HPV Testing Research Institutes , by Region USD Million (2017-2022)
  • Table 15. Cytology and HPV Testing: by Test Type(USD Million)
  • Table 16. Cytology and HPV Testing DNA-based Test , by Region USD Million (2017-2022)
  • Table 17. Cytology and HPV Testing RNA-based Test , by Region USD Million (2017-2022)
  • Table 18. South America Cytology and HPV Testing, by Country USD Million (2017-2022)
  • Table 19. South America Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 20. South America Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 21. South America Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 22. South America Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 23. Brazil Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 24. Brazil Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 25. Brazil Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 26. Brazil Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 27. Argentina Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 28. Argentina Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 29. Argentina Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 30. Argentina Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 31. Rest of South America Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 32. Rest of South America Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 33. Rest of South America Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 34. Rest of South America Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 35. Asia Pacific Cytology and HPV Testing, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 37. Asia Pacific Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 38. Asia Pacific Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 39. Asia Pacific Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 40. China Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 41. China Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 42. China Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 43. China Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 44. Japan Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 45. Japan Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 46. Japan Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 47. Japan Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 48. India Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 49. India Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 50. India Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 51. India Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 52. South Korea Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 53. South Korea Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 54. South Korea Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 55. South Korea Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 56. Taiwan Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 57. Taiwan Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 58. Taiwan Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 59. Taiwan Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 60. Australia Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 61. Australia Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 62. Australia Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 63. Australia Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 68. Europe Cytology and HPV Testing, by Country USD Million (2017-2022)
  • Table 69. Europe Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 70. Europe Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 71. Europe Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 72. Europe Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 73. Germany Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 74. Germany Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 75. Germany Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 76. Germany Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 77. France Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 78. France Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 79. France Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 80. France Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 81. Italy Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 82. Italy Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 83. Italy Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 84. Italy Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 85. United Kingdom Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 86. United Kingdom Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 87. United Kingdom Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 88. United Kingdom Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 89. Netherlands Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 90. Netherlands Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 91. Netherlands Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 92. Netherlands Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 93. Rest of Europe Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 94. Rest of Europe Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 95. Rest of Europe Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 96. Rest of Europe Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 97. MEA Cytology and HPV Testing, by Country USD Million (2017-2022)
  • Table 98. MEA Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 99. MEA Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 100. MEA Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 101. MEA Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 102. Middle East Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 103. Middle East Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 104. Middle East Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 105. Middle East Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 106. Africa Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 107. Africa Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 108. Africa Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 109. Africa Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 110. North America Cytology and HPV Testing, by Country USD Million (2017-2022)
  • Table 111. North America Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 112. North America Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 113. North America Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 114. North America Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 115. United States Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 116. United States Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 117. United States Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 118. United States Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 119. Canada Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 120. Canada Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 121. Canada Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 122. Canada Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 123. Mexico Cytology and HPV Testing, by Type USD Million (2017-2022)
  • Table 124. Mexico Cytology and HPV Testing, by Application USD Million (2017-2022)
  • Table 125. Mexico Cytology and HPV Testing, by End-Use USD Million (2017-2022)
  • Table 126. Mexico Cytology and HPV Testing, by Test Type USD Million (2017-2022)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Cytology and HPV Testing: by Type(USD Million)
  • Table 139. Cytology and HPV Testing Systems , by Region USD Million (2023-2028)
  • Table 140. Cytology and HPV Testing Assay Kits , by Region USD Million (2023-2028)
  • Table 141. Cytology and HPV Testing Services , by Region USD Million (2023-2028)
  • Table 142. Cytology and HPV Testing: by Application(USD Million)
  • Table 143. Cytology and HPV Testing Cervical Cancer Screening Test , by Region USD Million (2023-2028)
  • Table 144. Cytology and HPV Testing Head and Neck Cancer Screening Test , by Region USD Million (2023-2028)
  • Table 145. Cytology and HPV Testing Molecular Diagnostics , by Region USD Million (2023-2028)
  • Table 146. Cytology and HPV Testing Research Use , by Region USD Million (2023-2028)
  • Table 147. Cytology and HPV Testing Other , by Region USD Million (2023-2028)
  • Table 148. Cytology and HPV Testing: by End-Use(USD Million)
  • Table 149. Cytology and HPV Testing Hospitals , by Region USD Million (2023-2028)
  • Table 150. Cytology and HPV Testing Clinics , by Region USD Million (2023-2028)
  • Table 151. Cytology and HPV Testing Research Institutes , by Region USD Million (2023-2028)
  • Table 152. Cytology and HPV Testing: by Test Type(USD Million)
  • Table 153. Cytology and HPV Testing DNA-based Test , by Region USD Million (2023-2028)
  • Table 154. Cytology and HPV Testing RNA-based Test , by Region USD Million (2023-2028)
  • Table 155. South America Cytology and HPV Testing, by Country USD Million (2023-2028)
  • Table 156. South America Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 157. South America Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 158. South America Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 159. South America Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 160. Brazil Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 161. Brazil Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 162. Brazil Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 163. Brazil Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 164. Argentina Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 165. Argentina Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 166. Argentina Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 167. Argentina Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 168. Rest of South America Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 169. Rest of South America Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 170. Rest of South America Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 171. Rest of South America Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 172. Asia Pacific Cytology and HPV Testing, by Country USD Million (2023-2028)
  • Table 173. Asia Pacific Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 174. Asia Pacific Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 175. Asia Pacific Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 176. Asia Pacific Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 177. China Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 178. China Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 179. China Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 180. China Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 181. Japan Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 182. Japan Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 183. Japan Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 184. Japan Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 185. India Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 186. India Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 187. India Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 188. India Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 189. South Korea Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 190. South Korea Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 191. South Korea Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 192. South Korea Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 193. Taiwan Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 194. Taiwan Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 195. Taiwan Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 196. Taiwan Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 197. Australia Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 198. Australia Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 199. Australia Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 200. Australia Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 205. Europe Cytology and HPV Testing, by Country USD Million (2023-2028)
  • Table 206. Europe Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 207. Europe Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 208. Europe Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 209. Europe Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 210. Germany Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 211. Germany Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 212. Germany Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 213. Germany Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 214. France Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 215. France Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 216. France Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 217. France Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 218. Italy Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 219. Italy Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 220. Italy Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 221. Italy Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 222. United Kingdom Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 223. United Kingdom Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 224. United Kingdom Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 225. United Kingdom Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 226. Netherlands Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 227. Netherlands Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 228. Netherlands Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 229. Netherlands Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 230. Rest of Europe Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 231. Rest of Europe Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 232. Rest of Europe Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 233. Rest of Europe Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 234. MEA Cytology and HPV Testing, by Country USD Million (2023-2028)
  • Table 235. MEA Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 236. MEA Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 237. MEA Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 238. MEA Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 239. Middle East Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 240. Middle East Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 241. Middle East Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 242. Middle East Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 243. Africa Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 244. Africa Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 245. Africa Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 246. Africa Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 247. North America Cytology and HPV Testing, by Country USD Million (2023-2028)
  • Table 248. North America Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 249. North America Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 250. North America Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 251. North America Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 252. United States Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 253. United States Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 254. United States Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 255. United States Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 256. Canada Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 257. Canada Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 258. Canada Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 259. Canada Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 260. Mexico Cytology and HPV Testing, by Type USD Million (2023-2028)
  • Table 261. Mexico Cytology and HPV Testing, by Application USD Million (2023-2028)
  • Table 262. Mexico Cytology and HPV Testing, by End-Use USD Million (2023-2028)
  • Table 263. Mexico Cytology and HPV Testing, by Test Type USD Million (2023-2028)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cytology and HPV Testing: by Type USD Million (2017-2022)
  • Figure 5. Global Cytology and HPV Testing: by Application USD Million (2017-2022)
  • Figure 6. Global Cytology and HPV Testing: by End-Use USD Million (2017-2022)
  • Figure 7. Global Cytology and HPV Testing: by Test Type USD Million (2017-2022)
  • Figure 8. South America Cytology and HPV Testing Share (%), by Country
  • Figure 9. Asia Pacific Cytology and HPV Testing Share (%), by Country
  • Figure 10. Europe Cytology and HPV Testing Share (%), by Country
  • Figure 11. MEA Cytology and HPV Testing Share (%), by Country
  • Figure 12. North America Cytology and HPV Testing Share (%), by Country
  • Figure 13. Global Cytology and HPV Testing share by Players 2022 (%)
  • Figure 14. Global Cytology and HPV Testing share by Players (Top 3) 2022(%)
  • Figure 15. Global Cytology and HPV Testing share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 19. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Agilent Technologies, Inc. (United States) Revenue: by Geography 2022
  • Figure 21. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Becton, Dickinson and Company (United States) Revenue: by Geography 2022
  • Figure 23. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Qiagen N.V. (Germany) Revenue: by Geography 2022
  • Figure 25. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 29. Hologic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Hologic Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Cepheid Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cepheid Inc. (United States) Revenue: by Geography 2022
  • Figure 33. Seegene Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 34. Seegene Inc. (South Korea) Revenue: by Geography 2022
  • Figure 35. Takara Bio Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Takara Bio Inc. (Japan) Revenue: by Geography 2022
  • Figure 37. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Promega Corporation (United States) Revenue: by Geography 2022
  • Figure 39. Global Cytology and HPV Testing: by Type USD Million (2023-2028)
  • Figure 40. Global Cytology and HPV Testing: by Application USD Million (2023-2028)
  • Figure 41. Global Cytology and HPV Testing: by End-Use USD Million (2023-2028)
  • Figure 42. Global Cytology and HPV Testing: by Test Type USD Million (2023-2028)
  • Figure 43. South America Cytology and HPV Testing Share (%), by Country
  • Figure 44. Asia Pacific Cytology and HPV Testing Share (%), by Country
  • Figure 45. Europe Cytology and HPV Testing Share (%), by Country
  • Figure 46. MEA Cytology and HPV Testing Share (%), by Country
  • Figure 47. North America Cytology and HPV Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche Holding AG (Switzerland)
  • Agilent Technologies, Inc. (United States)
  • Becton, Dickinson and Company (United States)
  • Qiagen N.V. (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Abbott Laboratories (United States)
  • Hologic Inc. (United States)
  • Cepheid Inc. (United States)
  • Seegene Inc. (South Korea)
  • Takara Bio Inc. (Japan)
  • Promega Corporation (United States)
Additional players considered in the study are as follows:
DaAn Gene Co., Ltd (China) , Zytovision GmbH (Germany) , Arbor Vita Corporation (United States) , Fujirebio Diagnostics, Inc. (United States)
Select User Access Type

Key Highlights of Report


Nov 2023 247 Pages 54 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cytology and HPV Testing Market Quantitative research analysis
Global Cytology and HPV Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cytology and HPV Testing market are Roche Holding AG (Switzerland), Agilent Technologies, Inc. (United States), Becton, Dickinson and Company (United States), Qiagen N.V. (Germany), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States), Hologic Inc. (United States), Cepheid Inc. (United States), Seegene Inc. (South Korea), Takara Bio Inc. (Japan) and Promega Corporation (United States), to name a few.
is dominating the Cytology and HPV Testing Market.
"High Cost of the Test " is seen as one of the major challenges by many Industry Players of Cytology and HPV Testing Market
The Cytology and HPV Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Cytology and HPV Testing market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Cytology and HPV Testing Market Report?

Have a Query? Click Here

Other Related Reports

Bare Metal Stents Comprehensive Study by Type (Balloon Catheter, Self-Expandable Metallic Stent, Balloon Expandable Stent), Application (Large Vessel, Small Vessel), End Users (Hospitals, Ambulatory ...
$ 3450
Cold Plasma Comprehensive Study by Application (Surface Treatment, Sterilization & Disinfection, Coating, Finishing, Adhesion, Wound Healing, Others), Regime (Atmospheric Cold Plasma, Low-Pressure Co...
$ 3750
Proteomics Comprehensive Study by Application (Clinical Diagnostics, Drug Discovery, Other Applications), Services & Software (Core Proteomics Services, Bioinformatics Software & Services), Reagent (...
$ 3750
3D Cell Cultures Comprehensive Study by Type (Membrane Type, Foam / gel Type, Microcarriers Type), Application (Tissue Engineering, Tumor Model, Stem Cell Research, Drug Discovery, Regenerative Medic...
$ 3750
Medical Biomimetics Comprehensive Study by Type (Cardiovascular, Orthopedic (Prostheses, Exoskeleton), Ophthalmology, Dental, Others), Application (Wound Healing, Tissue Engineering, Drug Delivery, P...
$ 3350
Antimicrobial Susceptibility Testing Comprehensive Study by Type (Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing, Other Susceptibility T...
$ 3750